214 related articles for article (PubMed ID: 19348416)
1. Water-soluble prodrugs of the human immunodeficiency virus protease inhibitors lopinavir and ritonavir.
DeGoey DA; Grampovnik DJ; Flosi WJ; Marsh KC; Wang XC; Klein LL; McDaniel KF; Liu Y; Long MA; Kati WM; Molla A; Kempf DJ
J Med Chem; 2009 May; 52(9):2964-70. PubMed ID: 19348416
[TBL] [Abstract][Full Text] [Related]
2. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
Sohma Y; Hayashi Y; Ito T; Matsumoto H; Kimura T; Kiso Y
J Med Chem; 2003 Sep; 46(19):4124-35. PubMed ID: 12954064
[TBL] [Abstract][Full Text] [Related]
3. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans.
Kumar GN; Jayanti VK; Johnson MK; Uchic J; Thomas S; Lee RD; Grabowski BA; Sham HL; Kempf DJ; Denissen JF; Marsh KC; Sun E; Roberts SA
Pharm Res; 2004 Sep; 21(9):1622-30. PubMed ID: 15497688
[TBL] [Abstract][Full Text] [Related]
4. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir.
McCance-Katz EF; Moody DE; Smith PF; Morse GD; Friedland G; Pade P; Baker J; Alvanzo A; Jatlow P; Rainey PM
Clin Infect Dis; 2006 Dec; 43 Suppl 4():S235-46. PubMed ID: 17109310
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
[TBL] [Abstract][Full Text] [Related]
6. Response to the comparison of generic ritonavir (Ritomune, Cipla) and lopinavir/ritonavir tablets (Lopimune, Cipla) and the Abbott brand (Norvir soft-gel capsules and Kaletra tablets).
Chachad S; Gogtay J; Malhotra G; Purandare S
J Pharm Sci; 2010 Feb; 99(2):572-3; author reply 574. PubMed ID: 19718766
[No Abstract] [Full Text] [Related]
7. Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir.
Hickman D; Vasavanonda S; Nequist G; Colletti L; Kati WM; Bertz R; Hsu A; Kempf DJ
Antimicrob Agents Chemother; 2004 Aug; 48(8):2911-7. PubMed ID: 15273100
[TBL] [Abstract][Full Text] [Related]
8. Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor.
Agarwal S; Boddu SH; Jain R; Samanta S; Pal D; Mitra AK
Int J Pharm; 2008 Jul; 359(1-2):7-14. PubMed ID: 18455890
[TBL] [Abstract][Full Text] [Related]
9. Oximinoarylsulfonamides as potent HIV protease inhibitors.
Yeung CM; Klein LL; Flentge CA; Randolph JT; Zhao C; Sun M; Dekhtyar T; Stoll VS; Kempf DJ
Bioorg Med Chem Lett; 2005 May; 15(9):2275-8. PubMed ID: 15837308
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
L'homme RF; Nijland HM; Gras L; Aarnoutse RE; van Crevel R; Boeree M; Brinkman K; Prins JM; Juttmann JR; Burger DM
AIDS; 2009 Apr; 23(7):863-5. PubMed ID: 19352137
[TBL] [Abstract][Full Text] [Related]
11. Plasma and cerebrospinal pharmacokinetics and pharmacodynamics in subjects taking lopinavir/ritonavir.
Martin TM; Morse GD; Kurpewski J; Difrancesco R; Caliendo AM; Flanigan TP; Tashima KT
AIDS; 2006 Apr; 20(7):1085-7. PubMed ID: 16603871
[No Abstract] [Full Text] [Related]
12. Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.
Flentge CA; Randolph JT; Huang PP; Klein LL; Marsh KC; Harlan JE; Kempf DJ
Bioorg Med Chem Lett; 2009 Sep; 19(18):5444-8. PubMed ID: 19679477
[TBL] [Abstract][Full Text] [Related]
13. Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir.
Sinha S; Ali M; Baboota S; Ahuja A; Kumar A; Ali J
AAPS PharmSciTech; 2010 Jun; 11(2):518-27. PubMed ID: 20238187
[TBL] [Abstract][Full Text] [Related]
14. ABT-378: a second generation protease inhibitor.
Highleyman L
BETA; 1998 Oct; ():8, 55. PubMed ID: 11365998
[TBL] [Abstract][Full Text] [Related]
15. Orally bioavailable prodrugs of a BCS class 2 molecule, an inhibitor of HIV-1 reverse transcriptase.
Elworthy TR; Dunn JP; Hogg JH; Lam G; Saito YD; Silva TM; Stefanidis D; Woroniecki W; Zhornisky E; Zhou AS; Klumpp K
Bioorg Med Chem Lett; 2008 Dec; 18(24):6344-7. PubMed ID: 18993071
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.
la Porte C; van Heeswijk R; Mitchell CD; Zhang G; Parker J; Rongkavilit C
Antivir Ther; 2009; 14(4):603-6. PubMed ID: 19578247
[TBL] [Abstract][Full Text] [Related]
17. Effects of lopinavir-ritonavir combined therapy during the rat pregnancy. Morphological and biochemical aspects.
Cunha AM; Hagemann CC; Simões RS; Oliveira-Filho RM; Simões MJ; Soares JM; Maciel GA; Oliveira FH; Amed AA; Kulay L
Eur J Obstet Gynecol Reprod Biol; 2007 Jul; 133(1):60-3. PubMed ID: 16989938
[TBL] [Abstract][Full Text] [Related]
18. An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir.
ter Heine R; Van Waterschoot RA; Keizer RJ; Beijnen JH; Schinkel AH; Huitema AD
J Pharm Sci; 2011 Jun; 100(6):2508-15. PubMed ID: 21491455
[TBL] [Abstract][Full Text] [Related]
19. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.
Sham HL; Kempf DJ; Molla A; Marsh KC; Kumar GN; Chen CM; Kati W; Stewart K; Lal R; Hsu A; Betebenner D; Korneyeva M; Vasavanonda S; McDonald E; Saldivar A; Wideburg N; Chen X; Niu P; Park C; Jayanti V; Grabowski B; Granneman GR; Sun E; Japour AJ; Leonard JM; Plattner JJ; Norbeck DW
Antimicrob Agents Chemother; 1998 Dec; 42(12):3218-24. PubMed ID: 9835517
[TBL] [Abstract][Full Text] [Related]
20. Use of nonlinear mixed effect modeling for the intestinal absorption data: application to ritonavir in the rat.
Muñoz MJ; Merino-Sanjuán M; Lledó-García R; Casabó VG; Máñez-Castillejo FJ; Nácher A
Eur J Pharm Biopharm; 2005 Sep; 61(1-2):20-6. PubMed ID: 16005197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
